# Atoguanil BA Study

> **NCT04866602** · PHASE1 · COMPLETED · sponsor: **Medicines for Malaria Venture** · enrollment: 16 (actual)

## Conditions studied

- Bioavailability

## Interventions

- **DRUG:** Atoguanil
- **DRUG:** Malarone

## Key facts

- **NCT ID:** NCT04866602
- **Lead sponsor:** Medicines for Malaria Venture
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-17
- **Primary completion:** 2022-03-18
- **Final completion:** 2022-03-18
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2022-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04866602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04866602, "Atoguanil BA Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04866602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*